Cancer clinical trials in the region Provence-Alpes-Côte d'Azur

337 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 3 Breast cancer #NCT06841354

[TroFuse-011] Étude du SACITUZUMAB TIRUMOTECAN en monothérapie et en association avec le PEMBROLIZUMAB chez des participantes atteintes d'un cancer du sein triple négatif

HER2 Negative HR Negative Locally Advanced Metastatic None Systemic Treatment-Naive

9 recruiting sites

Merck Sharp & Dohme LLC

Phase 3 Breast cancer #NCT05078047

[MOIO] Étude comparant l'administration standard d'une immunothérapie (IO) vs la même IO administrée tous les 3 mois chez des patients en réponse après 6 mois d'IO standard

HER2 Negative HR Negative Locally Advanced Metastatic Immunotherapy

29 recruiting sites

UNICANCER

Phase 3 Prostate cancer #NCT06496581

[PEACE6-Poor Responders] Norme de soins +/- 177Lu-PSMA-617 chez les patients atteints de mHSPC de novo présentant une faible réponse du PSA

Adenocarcinoma Metastatic Hormone-sensitive None Hormone therapy

Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)

8 recruiting sites

UNICANCER

Phase 3 Lung cancer #NCT06692738

[ARTEMIDE-Lung02] Étude mondiale de phase III portant sur l'association de RILVEGOSTOMIG ou de PEMBROLIZUMAB à une chimiothérapie pour le traitement de première intention du cancer du poumon non à petites cellules épidermoïde métastatique

NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive

Immunotherapy

8 recruiting sites

AstraZeneca